Abstract
Lithium enjoys wide clinical use in the treatment of affective disorders, but the mechanism of its action in these conditions is still controversial. Recent studies have shown that lithium can interact with other antidepressant drugs to enhance their efficacy, perhaps by specific effects on serotonin (5-HT) function. A large body of independent evidence suggests that 5-HT function is abnormal in depression. This review documents preclinical evidence of lithium's effects on 5-HT function at the levels of precursor uptake, synthesis, storage, catabolism, release, receptors, and receptor-effector interactions. The weight of this evidence suggests that lithium's primary actions on 5-HT may be presynaptic, with many secondary postsynaptic effects. Studies in humans, using very different methodological approaches, generally suggest that lithium has a net enhancing effect on 5-HT function. These actions of lithium may serve to correct as-yet unspeccified abnormalities of 5-HT function involved in the pathogenesis of depression.
Original language | English |
---|---|
Pages (from-to) | 3-12 |
Number of pages | 10 |
Journal | Psychopharmacology |
Volume | 100 |
Issue number | 1 |
DOIs | |
State | Published - Mar 1990 |
Externally published | Yes |
Keywords
- Depression
- Lithium
- Serotonin